German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Introduction The Institute for Quality and Efficiency in Health Care (IQWiG), in its pursuit of promoting evidence-based healthcare decisions, continuously refines its
In this post, I’m following up on the key points on the real-world evidence (RWE) data collection in Germany with an IQWiG
Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in
This week, we are having a brief look at two brief reports on PROs recently published by the IQWiG. We’ll cover: As
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:
Registry-based RCT could provide important answers on the optimal treatments and their sequencing for RRMS, but a lack of reimbursement hinders these
After several years of discussions, the EU will start to conduct joint HTAs in 2024. This process will be organized and overseen
The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,
The IQWiG not only examines the benefits and harms of medical interventions for early benefit assessments but also produces independent, evidence-based reports
The IQWiG has just published draft version 6.1 of its “General methods”. The General Methods describe the work procedures of the IQWiG,